Selective GLP-1 Receptor Agonist
Semaglutide is a selective GLP-1 receptor agonist developed by Novo Nordisk, first approved by the FDA in December 2017 for type 2 diabetes under the trade name Ozempic (subcutaneous) and subsequently as Rybelsus (oral) in September 2019 and Wegovy (higher-dose SC for obesity) in June 2021. It is a modified analog of native human GLP-1(7-37) with 94% structural homology, engineered with two key modifications: an Aib substitution at position 2 for DPP-IV resistance and a C18 fatty diacid chain at Lys26 enabling strong non-covalent albumin binding. These modifications extend the plasma half-life from the 2-minute half-life of native GLP-1 to approximately 7 days, enabling once-weekly subcutaneous dosing. Semaglutide is the most extensively published incretin compound in the medical literature, with over 5,000 peer-reviewed publications and data from more than 30,000 clinical trial participants across the SUSTAIN, PIONEER, STEP, and SELECT programs. The STEP-1 trial (n=1,961) demonstrated 14.9% mean weight reduction at 68 weeks with the 2.4 mg dose, establishing semaglutide as the reference standard for GLP-1 receptor agonist research. The SELECT cardiovascular outcomes trial subsequently showed a 20% reduction in major adverse cardiovascular events, making semaglutide the first obesity medication to demonstrate cardiovascular risk reduction in non-diabetic patients.
Over 5,000 publications and 30,000+ trial participants make semaglutide the most thoroughly studied GLP-1 agonist.
STEP-1 showed 14.9% mean weight loss at 68 weeks — the clinical benchmark for selective GLP-1 agonist efficacy.
SELECT trial demonstrated 20% reduction in MACE events in overweight/obese individuals without diabetes.
SUSTAIN trials showed HbA1c reductions of 1.5–1.8% across dose levels, with high proportions reaching target glycemia.
Emerging research explores GLP-1R activation in neurodegeneration, with Alzheimer's trials underway.
The 7-day half-life from C18 fatty diacid albumin binding allows convenient once-weekly administration.
Rybelsus formulation with SNAC absorption enhancer demonstrates that peptides can achieve oral delivery — a pharmacological milestone.
FLOW trial showed significant reduction in kidney disease progression in patients with T2DM and chronic kidney disease.
Semaglutide binds with high affinity and selectivity to the GLP-1 receptor, a class B GPCR expressed on pancreatic beta cells, hypothalamic neurons, cardiac tissue, the GI tract, and kidney. Upon receptor binding, semaglutide activates Gαs-coupled adenylyl cyclase, increasing intracellular cAMP levels and triggering PKA-dependent signaling cascades that vary by tissue type. In the pancreas, semaglutide potentiates glucose-dependent insulin secretion by closing KATP channels on beta cells, increasing intracellular calcium, and promoting insulin granule exocytosis — critically, only when blood glucose exceeds the euglycemic threshold, minimizing hypoglycemia risk. Simultaneously, GLP-1R activation on alpha cells suppresses glucagon secretion, reducing hepatic glucose output. In preclinical models, semaglutide also promotes beta-cell proliferation and inhibits apoptosis, suggesting potential for beta-cell mass preservation. Central appetite regulation occurs primarily through GLP-1R activation in the hypothalamic arcuate nucleus and the nucleus tractus solitarius in the brainstem. This stimulates POMC/CART anorexigenic neurons while inhibiting NPY/AgRP orexigenic pathways, producing sustained appetite suppression. Semaglutide also delays gastric emptying through vagal afferent modulation, prolonging postprandial satiety. The cardiovascular benefits observed in SELECT appear to involve direct anti-inflammatory effects on vascular endothelium, reduced macrophage plaque infiltration, and improved endothelial nitric oxide signaling — effects that are GLP-1R-dependent but independent of glucose lowering.
STEP trials (1–5) established 2.4 mg weekly as the reference dose for weight reduction research in overweight/obese populations.
Phase 3 CompleteSELECT trial (n=17,604) demonstrated 20% MACE reduction in overweight/obese patients without diabetes — a landmark result.
Phase 3 CompleteEVOKE and EVOKE+ trials evaluating semaglutide for early-stage Alzheimer's disease based on GLP-1R neuroprotection data.
Phase 3 ActiveFLOW trial showed significant reduction in kidney disease progression in T2DM patients with CKD.
Phase 3 CompletePhase 2 data showed NASH resolution in 59% of patients receiving 0.4 mg daily semaglutide vs 17% placebo.
Phase 2 CompletePIONEER program studying oral semaglutide with SNAC absorption enhancer — paradigm for oral peptide pharmacology.
Active| Period | Dose | Frequency | Notes |
|---|---|---|---|
| 1–4 | 0.25 mg | Once weekly | Initiation dose — not therapeutic, GI acclimation only |
| 5–8 | 0.5 mg | Once weekly | First therapeutic dose level |
| 9–12 | 1.0 mg | Once weekly | Standard maintenance dose for glycemic control |
| 13–16 | 1.7 mg | Once weekly | Escalation toward obesity-dose range |
| 17+ | 2.4 mg | Once weekly | Maximum dose — used in STEP trials for weight management |
Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide is a dual GLP-1/GIP agonist. In the head-to-head SURPASS-2 trial, tirzepatide 15 mg produced greater weight loss and glycemic improvement than semaglutide 1 mg. However, semaglutide has the most extensive safety and efficacy database of any incretin compound, with over 5,000 publications and cardiovascular outcomes data (SELECT trial) that tirzepatide is still building.
The PIONEER trials showed that oral semaglutide (Rybelsus, with SNAC absorption enhancer) is effective for glycemic control but produces somewhat lower weight loss than injectable semaglutide at equivalent doses. This is likely due to lower and more variable bioavailability with oral dosing. Oral semaglutide must be taken on an empty stomach with no more than 4 oz of water, 30 minutes before food.
Reconstitute lyophilized semaglutide with bacteriostatic water at 1 mg/mL concentration. Add solvent slowly against the vial wall, swirl gently until fully dissolved. The solution should be clear and colorless. Store at 2–8°C and use within 28–30 days. Do not shake vigorously or freeze the reconstituted solution.
SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled 17,604 overweight/obese patients without diabetes and demonstrated a 20% reduction in MACE (cardiovascular death, non-fatal MI, non-fatal stroke). This was the first trial to show cardiovascular risk reduction with an obesity medication in non-diabetic patients — a landmark result that fundamentally changed how excess weight is viewed as a cardiovascular risk factor.
Weight loss with semaglutide typically includes 25–40% lean mass loss alongside fat mass reduction, consistent with the general pattern seen in caloric restriction. This has led to research interest in combining GLP-1 agonists with resistance training protocols or anabolic agents to preserve lean tissue. The body composition impact should be considered in research protocol design.
Need help choosing a peptide?
Try the AI Coach →